老年患者生物瓣主动脉瓣置换的荟萃分析与微观模拟
该系统综述纳入42项研究、12842例平均年龄76.5岁的老年主动脉瓣置换患者,汇总早期死亡风险5.42%,血栓栓塞率1.83%/年,出血率0.75%/年。微观模拟显示75岁患者预期寿命9.8年(一般人群10.2年),终生出血风险7%、血栓栓塞17%、再干预9%。结论支持老年患者使用生物瓣。
要点
- 老年生物瓣主动脉瓣置换早期死亡风险5.42%,血栓栓塞1.83%/年,出血0.75%/年。
- 75岁患者术后预期寿命9.8年,与一般人群10.2年相近。
- 生物瓣结构衰败与再干预风险低,支持老年患者选择生物瓣。
核心结论
- 生物瓣结构衰败和再干预风险低,支持需要主动脉瓣置换的老年患者使用生物瓣。
- 主动脉瓣置换后估计预期寿命与一般人群相当。
研究设计与样本
- 系统综述纳入2000年1月1日至2016年9月1日发表的42项研究、34个患者队列。
- 共12842例患者,平均年龄76.5±5.5岁,随访55437患者年,汇总平均随访5.0±3.3年。
主要发现
- 汇总早期死亡风险5.42%(95%CI 4.49-6.55)。
- 血栓栓塞率1.83%/年(95%CI 1.28-3.61),出血率0.75%/年(95%CI 0.50-1.11)。
- 结构衰败基于汇总时间-事件数据(Gompertz;shape 0.124,rate 0.003)。
- 75岁患者估计预期寿命9.8年(一般人群10.2年),终生出血风险7%、血栓栓塞风险17%、再干预风险9%。
临床怎么用
- 结果可用于告知老年患者生物瓣主动脉瓣置换后的预期结局,支持治疗决策。
- 可作为适合手术患者经导管主动脉瓣植入及其他未来替代治疗长期结局的基准。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To support decision-making in aortic valve replacement (AVR) in elderly patients, we provide a comprehensive overview of outcome after AVR with bioprostheses. METHODS: A systematic review was conducted of studies reporting clinical outcome after AVR with bioprostheses in elderly patients (mean age ≥70 years; minimum age ≥65 years) published between January 1, 2000, to September 1, 2016. Reported event rates and time-to-event data were pooled and entered into a microsimulation model to calculate life expectancy and lifetime event risks. RESULTS: Forty-two studies reporting on 34 patient cohorts were included, encompassing a total of 12,842 patients with 55,437 patient-years of follow-up (pooled mean follow-up 5.0 ± 3.3 years). Pooled mean age was 76.5 ± 5.5 years. Pooled early mortality risk was 5.42% (95% confidence interval [CI], 4.49-6.55), thromboembolism rate was 1.83%/year (95% CI, 1.28-3.61), and bleeding rate was 0.75%/year (95% CI, 0.50-1.11). Structural valve deterioration (SVD) was based on pooled time to SVD data (Gompertz; shape: 0.124, rate: 0.003). For a 75-year-old patient, this translated to an estimated life expectancy of 9.8 years (general population: 10.2 years) and lifetime risks of bleeding of 7%, thromboembolism of 17%, and reintervention of 9%. CONCLUSIONS: The low risks of SVD and reintervention support the use of bioprostheses in elderly patients in need of AVR. The estimated life expectancy after AVR was comparable with the general population. The results of this study inform patients and clinicians about the expected outcomes after bioprosthetic AVR and thereby support treatment decision-making. Furthermore, our results can be used as a benchmark for long-term outcomes after transcatheter aortic valve implantation in patients who were eligible for surgery and other (future) alternative treatments (eg, tissue-engineered heart valves).
引用
- Huygens SA, Etnel JRG, Hanif M, et al. Bioprosthetic aortic valve replacement in elderly patients: Meta-analysis and microsimulation. J Thorac Cardiovasc Surg. 2018. PMID: 30501946. doi:10.1016/j.jtcvs.2018.10.040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。